Jupiter Neurosciences (JUNS) Liabilities and Shareholders Equity (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Liabilities and Shareholders Equity of $5.6 million for Q4 2025, down 10.29% year-over-year from $6.2 million in Q4 2024, and up 115.97% quarter-over-quarter from $2.6 million in Q3 2025.
Jupiter Neurosciences (JUNS) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $5.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 10.29% year-over-year to $5.6 million; the TTM figure through Dec 2025 stood at $17.1 million (up 171.49% YoY), while the FY2025 annual figure was $5.6 million, down 10.29% from the prior year.
- Liabilities and Shareholders Equity improved to $5.6 million in Q4 2025 per JUNS's latest filing, from $2.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $6.2 million in Q4 2024 and bottomed at $85546.0 in Q3 2024.
- Historically, Liabilities and Shareholders Equity has averaged $3.4 million across 3 years, with a median of $4.0 million in 2025.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 4074.12% — and 2025, when it fell 10.29%.
- Jupiter Neurosciences' Liabilities and Shareholders Equity stood at $148592.0 in 2023, then jumped by 4074.12% to $6.2 million in 2024, then declined by 10.29% to $5.6 million in 2025.
- Business Quant data shows JUNS's Liabilities and Shareholders Equity at $5.6 million in Q4 2025, $2.6 million in Q3 2025, and $4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.56 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 4.96 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 85,546.00 |
| Dec 31, 2023 | 148,592.00 |